Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease?

Clinical Cardiology

Volumn 36, Issue 2, 2013, Pages 110-116

  Eisen, Alon ^a   Benderly, Michal ^b   Goldbourt, Uri ^c   Haim, Moti ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC HYPERTENSION; URIC ACID BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERURICEMIA; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION; URIC ACID;

EID: 84873704608     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22083     Document Type: Article

References (24)

1. Holme L, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolopoprotein mortality risk study (AMORIS). J Intern Med. 2009; 266: 558-570.
2. Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005; 118: 816-826. (Pubitemid 41097455)
3. Gagliardi A, Miname MH, Santos RD., Uric acid: a marker of increased cardiovascular risk. Athersclerosis. 2009; 202: 11-17.
4. Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008; 125: 232-239.
5. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol. 2000; 10: 136-143. (Pubitemid 30171270)
6. Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC study. Atherosclerosis. 2006; 187: 401-407. (Pubitemid 43963022)
7. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54: 2688-2696. (Pubitemid 44208638)
8. Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta- analysis. Congest Heart Fail. 2011; 17: 25-30.
9. Krishnan E., Hyperuricemia and incident heart failure. Circ Heart Fail. 2009; 2: 556-562.
10. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol. 2011; 151: 143-147.
11. Wu AH, Ghali JK, Neuberg GW, et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J. 2010; 160: 928-933.
12. The BIP, Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102: 21-27.
13. The BIP, Study Group. Rationale and design of a secondary prevention trial of increasing serum HDL cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease. Am J Cardiol. 1993; 71: 909-915.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
15. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706. (Pubitemid 29126745)
16. Gray RJ., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
17. Lunn M, McNeil D., Applying Cox regression to competing risks. Biometrics. 1995; 51: 524-532.
18. Glynn RJ, Rosner B, Christen WG., Evaluation of risk factors for cataract types in a competing risks framework. Ophthalmic Epidemiol. 2009; 16: 98-106.
19. Harrell FE, Lee KL, Mark DB., Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387. (Pubitemid 26072233)
20. Samuelsson O, Wilhelmsen L, Pennert K, et al. Angina pectoris, intermittent claudication and congestive heart failure in middle-aged male hypertensives. Development and predictive factors during long-term anti-hypertensive care. The primary preventive trial. Acta Med Scand. 1987; 221: 23-32. (Pubitemid 17041664)
21. Ingelsson E, Arnlov J, Sundstrom J, et al. Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005; 46: 2054-2060.
22. Strasak A, Ruttmann E, Brant LJ, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008; 54: 273-284. (Pubitemid 351302628)
23. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004; 16: 1546-1551. (Pubitemid 38970476)
24. Tamariz L, Agarwal S, Soliman EZ, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011; 108: 1272-1276.